Literature DB >> 14970400

Clinical utility of anti-CCP antibodies in the differential diagnosis of elderly-onset rheumatoid arthritis and polymyalgia rheumatica.

M Lopez-Hoyos1, C Ruiz de Alegria, R Blanco, J Crespo, M Peña, V Rodriguez-Valverde, V M Martinez-Taboada.   

Abstract

BACKGROUND: In a significant number of patients the differential diagnosis between elderly-onset rheumatoid arthritis (EORA) and polymyalgia rheumatica (PMR) is very difficult because of the lack of specific serum markers. Anti-cyclic citrullinated peptide antibodies (anti-CCP Abs) have recently been shown to be highly specific for rheumatoid arthritis (RA). This is the first study addressing the utility of these antibodies in the differential diagnosis between EORA and PMR.
METHODS: Serum samples from 57 EORA patients and 49 PMR patients were studied for the presence of anti-CCP Abs and rheumatoid factor (RF). As controls, samples from 41 RA patients (age at onset <60 yr) and 24 aged healthy subjects were analysed.
RESULTS: Sixty-five per cent of EORA patients had anti-CCP Abs, whereas none of the PMR patients or the aged healthy subjects was positive for those antibodies. Ten of the EORA patients started with polymyalgic symptoms and two of them were positive for anti-CCP Abs. Interestingly, there was a significant correlation between anti-CCP Abs and RF in EORA but not in young RA patients.
CONCLUSIONS: The presence of anti-CCP Abs in a patient with clinical symptoms of PMR must be interpreted as highly suggestive of EORA.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14970400     DOI: 10.1093/rheumatology/keh143

Source DB:  PubMed          Journal:  Rheumatology (Oxford)        ISSN: 1462-0324            Impact factor:   7.580


  29 in total

Review 1.  [Polymyalgia rheumatica: myalgic syndrome or occult vasculitis?].

Authors:  B Hellmich; W L Gross
Journal:  Internist (Berl)       Date:  2005-11       Impact factor: 0.743

2.  Coexistence of the monostatic Paget's disease, sensorimotor neuropathy and elderly onset rheumatoid arthritis.

Authors:  Ali Aydeniz; Savaş Gürsoy; Sabri Zincirkeser
Journal:  Rheumatol Int       Date:  2008-10-12       Impact factor: 2.631

Review 3.  Anti-citrullinated peptide antibody assays and their role in the diagnosis of rheumatoid arthritis.

Authors:  Rohit Aggarwal; Katherine Liao; Raj Nair; Sarah Ringold; Karen H Costenbader
Journal:  Arthritis Rheum       Date:  2009-11-15

4.  Serum cytokines and steroidal hormones in polymyalgia rheumatica and elderly-onset rheumatoid arthritis.

Authors:  M Cutolo; C M Montecucco; L Cavagna; R Caporali; S Capellino; P Montagna; L Fazzuoli; B Villaggio; B Seriolo; A Sulli
Journal:  Ann Rheum Dis       Date:  2006-04-27       Impact factor: 19.103

Review 5.  [Diagnostics and treatment of polymyalgia rheumatica].

Authors:  C Dejaco; E L Matteson; F Buttgereit
Journal:  Z Rheumatol       Date:  2016-09       Impact factor: 1.372

6.  [Is the treatment response in elderly patients with rheumatoid arthritis diminished? Results of a prospective study over 3 months].

Authors:  C Fiehn; S Kessler
Journal:  Z Rheumatol       Date:  2009-02       Impact factor: 1.372

7.  The Clinical Application of Anti-CCP in Rheumatoid Arthritis and Other Rheumatic Diseases.

Authors:  Ct Chou; Ht Liao; Ch Chen; Ws Chen; Hp Wang; Ky Su
Journal:  Biomark Insights       Date:  2007-05-03

8.  Pattern of Young and Old Onset Rheumatoid Arthritis (YORA and EORA) Among a Group of Egyptian Patients with Rheumatoid Arthritis.

Authors:  Abdou S El-Labban; Hanaa A S Abo Omar; Rawhya R El-Shereif; Fatma Ali; Tarek M El-Mansoury
Journal:  Clin Med Insights Arthritis Musculoskelet Disord       Date:  2010-05-20

Review 9.  Update on autoantibodies in rheumatoid arthritis.

Authors:  S Louis Bridges
Journal:  Curr Rheumatol Rep       Date:  2004-10       Impact factor: 4.592

10.  Cartilage Oligomeric Matrix Protein (COMP): A Biomarker of Arthritis.

Authors:  Susan Tseng; A Hari Reddi; Paul E Di Cesare
Journal:  Biomark Insights       Date:  2009-02-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.